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Abstract: Introduction: The prostate is a gland that surrounds men's urethra and helps to produce semen. In 
developed countries, prostate cancer (PCa.) is the second most common and lethal disease in men. 
Hereditary history of PCa. is a major contributor to this cancer? While a number of genetic and mo-
lecular changes have been reported in PCa, the general picture of the genetic aberrations is needed 
in Iranian population.  
Methods: In this study, a literature search from Jan. 2000 to June 2018 was performed through the 
PubMed, Google Scholar, Scopus, Web of Science, IranMedex, MEDLIB, IranDoc and Scientific Infor-
mation databases using the keywords “genetic polymorphisms”, “prostate cancer”, “Iranian, and 
compare with regional and international population”.  
Results: The results revealed that several genome-wide association studies (such as rs2070744 
and rs1799983 in the eNOS, rs243865 in the MMP2, rs1902023 in the UGT2B15, rs266882 in the 
PSA, rs10625775443 in the GNB3, rs 1800682 in the FAS, rs12052398 and rs13393577 in the 
ERBB4, rs181133 in the MTHFR, rs 1805087 in the MTR, rs1805355 in the MSH3, (rs60271534 in 
the CYP19, rs2234693 and rs9340799 in the ER-a, rs4986938 and rs1256049 in the ER-b) and sin-
gle-nucleotide polymorphisms in important pathways (such as angiogenesis, androgen receptor 
binding site, cell signaling, folate metabolism, DNA repair, hormone synthesis and metabolism pol-
ymorphisms ) involved in prostate cancer occurrence and mechanism could serve as candidate bi-
omarkers for the detection of PCa. The most important results of the all studied articles is summa-
rized in Table 1 and 2.  
Conclusion: Several studies have been conducted on the family history of PCa. The main reason for 
this gathering is to inherit the involved genes. Additional studies are required to decipher precisely 
the gene combinations and personalize the management of prostate cancer. This article is the first 
comprehensive overview of genetic investigations of gene polymorphisms on PCa. in Iran. 
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1. Introduction 
PCa. is the most common malignant cancer in 
men. Most of the prostate cancers will never develop 
symptoms and remain undiagnosed during life though 
epidemiologic studies about prostate cancer include 
those patients who are diagnosed either due to the rise 
of serum level of PSA or clinical symptoms which are 
called clinical prostate cancers. According to 2010 
men's cancer statistics, PCa. is the most commonly diag-
nosed cancer, with the highest incidence (28%) and the 
second leading cause of death (11%) after lung cancer 
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(29%)(16). In general, out of every six men, 1 person 
will develop PCa. during their life, and the risk of devel-
oping is increased by age. Epidemiologic publications 
showed that there is alteration in the geographic and ra-
cial distribution of PCa. The incidence of clinical PCa. 
around the world is close to 50 cases per 100,000 pop-
ulations, which varies between 3.9 in India and 178.8 in 
100,000 people in the American Blacks. According to the 
2008 report, an average annual Age-Standardized inci-
dence Rates (ASR) per 100,000 person-years, in devel-
oping countries, in advanced countries and, in the world 
is 11.9, 61.7,and 27.9, respectively(20). Despite the de-
cline in the incidence and, the death of PCa. in the United 
States and some other Western countries, the incidence, 
and death rate of this cancer is increasing in less devel-
oped and developing countries(21). The rate of PCa. in 
Asian countries is much lower than that reported by the 
Western population, but it is still rising in Asian coun-
tries(20). In Iran, the prevalence of PCa. in five prov-
inces of Iran between 1996 and 2000 was 5.1 per 
100,000 people of a year, while the cancer registry sys-
tem has not recorded all cases, which means that the re-
ported amounts are less than statistics. Clinical PCa. in 
Iran as in other developing countries is increasing. PCa. 
is the eighth cause of cancer deaths in Iran(20). The 
main reason for this gathering is to inherit the involved 
genes. The main difference in the incidence of PCa. 
among men in developed countries and in Asian coun-
tries is the important differences in their lifestyle. Diet, 
sexual behavior patterns, alcohol consumption, ultravi-
olet radiation, are important factors in this regard (31, 
32). Few investigations have been directed to the risk 
factors for PCa. in the Iranian men. The incidence of PCa. 
in Iran is low as compared to the Western countries. 
This can partly be clarified by absence nationwide 
screening program, quality of cancer registration sys-
tem and younger age population in Iran (33, 34). Be-
cause of the significant role of genetic factors, there has 
been increasing focus on the role of single nucleotide 
DNA variation. The single nucleotide polymorphisms 
(SNPs) mark varieties in our susceptibility and used for 
cancer association studies. Several authors have pub-
lished gene polymorphisms in association with spo-
radic, hereditary, and familial-based PCa.(36).This arti-
cle is a comprehensive overview of genetic investiga-
tions of gene polymorphisms on PCa. in Iran. SNPs in the 
angiogenesis, DNA repair, cell cycle control, cell signal-
ing, androgen receptor (AR), regulating gene expres-
sion, regulating Immune responses, hormone synthesis 
and metabolism, drug metabolizer, detoxification and 
resistance, folate metabolism, renin -angiotensin sys-
tem studies are reviewed in the present article. Since ge-
netic variations are inheritable factors, and their fre-
quency differs in different populations with varied eth-
nicity and background, the purpose of this review article 
was investigated previous reports regarding the associ-
ation between genetic polymorphisms in different path-
ways and PCa. risk in an Iranian population. 
2. Method 
2.1. Search strategy: 
A rapid literature search strategy was conducted for all 
English and Farsi language papers published until July 
2018. The search was conducted using the electronic da-
tabases PubMed, Google Scholar, Scopus, Web of Sci-
ence, IranMedex, MEDLIB, IranDoc and Scientific Infor-
mation databases. The search strategy included the key-
words “genetic polymorphisms”, “prostate cancer”, “Ira-
nian, regional and international population”. Further-
more, the reference lists of the extracted articles were 
checked to find other sources. 
2.2. Inclusion and exclusion criteria: 
The inclusion criteria were: (1) case–control studies de-
signed to investigate the relationship between SNPs and 
prostate cancer risk; (2) available information on the 
genotype or allele frequencies in case and control 
groups; (3) selection of articles with the largest number 
of samples for comparison between studies in Iran and 
other countries. Papers repeated in more than one data-
base were counted just once. The excluded elements en-
compassed: studies based on non-human research; 
studies with insufficient data and with no allele frequen-
cies for each polymorphism; non-original studies such 
as Letters to the Editor, and brief communication were 
excluded. Two authors (Amini Nik S. and Soleimani M.) 
independently assessed and selected studies for final 
analysis; discrepancies were resolved by consensus. 
2.3. Data extraction: 
According to the strategy adopted initially, 672 manu-
scripts were found. After reviewing the titles, abstracts 
and manuscripts entirely cited, the total of 195 articles 
were obtained and selected according to the eligibility 
criteria. The following data were extracted from each in-
cluded study: (1) first author's name and year of publi-
cation, (2) gene function, (3) ethnicity, (4) country, (5) 
number of cases and controls, (6) allele or genotype fre-
quencies of cases and controls. Missing data were exam-
ined by contacting the first or corresponding author. At 
first, the importance of genetic review has been pre-
sented in the form of family history, followed by genes 
and polymorphisms in separate functional groups. 
Then, a summary of the performance of each pathway 
and the role of the studied genes mentioned and, finally, 
the association between polymorphisms and prostate 
cancer in Iran are presented and the comparison of the 
results with the regional and global countries has been 
carried out. 
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Angiogenesis MMP2 102/139 No (4) 
 MMP2 50/50 No (5) 
 eNOS 100/340 Yes (10) 
 eNOS 95/111 No (14) 
 VEGF 50/50 Yes (17) 
     
DNA repair ApE1 100/100 Yes (22) 
 MSH3 18/60 Yes (27) 
 XPC 154/205 No (30) 
     
AR Pathway CAG repeat length 110/100 Yes (12) 
 UGT 120/120 Yes (35) 
 PSA 95/111 No (38) 
     
Cell cycle regulators MDM2 103/142 Yes (39) 
 TP53 103/142 Yes (39) 
 TP53 40/80 No (44) 
 TP53 68/85 No (49) 
 TP53 187/185 Yes (51) 
 TP53 45/45 Yes (58) 
 PRKCI 169/182 Yes (59) 
     
Cell Signalling G protein 172/344 Yes (63) 
 ERBB4 169/182 No (64) 
 FAS 100/100 No (66) 
 TGF-β1 --/-- Yes (69) 
 LAPTM4B 168/176 Yes (70) 
     
Regulating Gene Expression SETD8(miR-502) 169/182 Yes (72) 
 miR-499 169/182 Yes (1) 
 
miR-196a2, miR-146a and 
miR-149 
169/182 No (1) 
 ANRIL 125/220 No (73) 
 PRNCR1 178/180 Yes (25) 




177/170 Yes (92) 
     
Regulating Immune responses RNASEL 61-101 No (45) 
 RNASEL 40/80 No (47) 
 IL1A 150/155 Yes (55) 
     
Hormone synthesis and metabolism CYP17 74/128 Yes (67) 
 CYP17 150-150 Yes (77) 
 CYP19 59/95 No (83) 
 MSMB 169/182 Yes (97) 
 SHBG 120/120 Yes (111) 
 ER-a and ER-b 162/324 Yes/No (113) 
     
Drug metabolizer, detoxification and 
resistance 
GST 60/60 No (3) 
 GST 110/100 No (12) 
 GST 168/336 Yes (18) 
 ABCC1 45/45 Yes (58) 
 NAT2 147/207 No (54) 
 COMT 41/193 Yes (69) 
     
Folate metabolism MTHFR 10,832/ 11,993 No (103) 
 MTHFR 67/75 No (93) 
 FVL, PTH,MTHFR 30/40 No (110) 
 MTR 100/100 Yes (120) 
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3. Result 
3.1. Family history, related polymorphisms and 
prostate cancer: 
PCa. diagnosis in a family member is called family PCa. 
and the prevalence rate of it is estimated to be around 
20%. The presence of similar genes, lifestyle, and envi-
ronmental status are the reasons associated with it(50). 
Articles showed that PCa. risk is 2.3 times higher in the 
first-degree family members than in others(56). Inher-
ited PCa. arises when a gene mutation is transmitted 
from one generation to the next and occurs in men who 
have one of the following features: at least 3 of their 
first-degree relatives are affected by PCa.; three genera-
tions of a family or two generations or more of close rel-
atives are affected by PCa. (50, 65). In the following, in 
the table 1, the polymorphisms studied in Iran were 
compared on the basis of the relevant gene function and 
their association and in the table 2, the comparison was 
made on the basis of P-value with other countries. 
3.2. Angiogenesis-Related Genes: 
Angiogenesis refers to the process of the formation of 
new blood vessels, which is important for the natural 
development of the body and depends on the exact bal-
ance between natural stimulants and inhibitors. If this 
balance is collapsed from the normal state, conditions 
for diseases such as cancers occurred. In general, this 
process is affected by a variety of factors, including a se-
ries of cellular events such as migration, proliferation, 
and differentiation of endothelial cells, and ultimately 
vascular formation, puberty and ultimate restoration. 
For this reason, angiogenesis inhibition as a contrib-
uting factor in conventional cancer treatments such as 
chemo and radiation therapy has attracted the attention 
of researchers who are studying in this area. MMP, 
VEGF, and NOS are important genes in this process. The 
main angiogenic factor is vascular endothelial growth 
factor (VEGF). Hypoxia is one of the factors that induce 
angiogenesis. Several angiogenic compounds, such as 
VEGF, are induced by hypoxia. The presence of high-
density vascular tumor regions in PCa. has a poor prog-
nosis. Oncogenetic changes in tumor cells may contrib-
ute to angiogenesis by inducing angiogenic factors. The 
mutation in the oncogenic genes of ras-K, ras-H and src-
V induces VEGF expression. Mehini et al. in 2015 re-
vealed a significant difference of variants VEGF460 C / 
T in term of T polymorphism in prostate cancer patients 
compared with normal group(17). In another study, in 
2008, researchers stated that polymorphisms and hap-
lotypes of VEGF would not change the risk of PCa.(78). 
Also, in Taiwan the results showed that the polymor-
phism 460 C / T of VGEF gene would be a biological 
marker for PCa.(17). Moreover, Onen et al. did not find 
any significant association between 460C/T polymor-
phism and PCa. in the Turkish population(57) which 
agrees with Fukuda’s results(94).On the other hand, 
Matrix metalloproteinase (MMPs) are the most im-
portant extracellular matrix degrading proteases whose 
key roles in invasion, metastasis, and angiogenesis have 
been proven. MMP2 has a collagenase activity, its over-
expression causes base membrane ruptures and plays 
the main role in metastasis(103). Many several re-
searches have evaluated the association between MMP2 
-1306 CT polymorphism and PCa. in different popula-
tions. While some of these investigations have 
confirmed the role of MMP2-1306 CT polymorphism in 
PCa. development and metastasis, others have failed to 
establish any relationships between them. In 2015, a 
study by Adabi showed that there was not association 
between MMP2 -1306 C/T polymorphism and risk of 
PCa. (p = 0.08).  They explained, in a population of Ira-
nian men with PCa., the 1306 C/T MMP2 polymorphism 
showed no association with either serum PSA levels or 
with the risk of metastasis of PCa. and seems not to be a 
genetic susceptibility factor for the development of PCa. 
(4). Also, consistently with their results, Shajarehpoor et 
al in 2017 could not find any association too(5).  In a 
meta-analysis, researcher reported that the frequency 
of T allele in MMP2 -1306 CT polymorphism to be much 
higher in in European populations than Asian popula-
tions (114). Another meta-analysis by Liu et al. showed 
that there is no statistical evidence between MMP2 
1306 C/T polymorphism and risk of metastasis(116). In 
India, Srivastava et al. study showed that CT genotype 
was significantly associated with a 1.68-fold increased 
risk of PCa.(7). In a survey in Turkey, Yaykasli et al. re-
ported the frequency of CT genotype in patients to be 
2.17 times higher than that control group(122). The dis-
crepancy between the results of different investigations 
may be associated with the race and the incidence of 
PCa. in an Iranian population(5). 
Various investigations have demonstrated that nitric 
oxide (NO) and nitric oxide synthase (NOS) system plays 
a key role in carcinogenesis. Gene polymorphisms of en-
dothelial nitric oxide synthase (eNOS) remarkably affect 
serum NO concentrations(130). Publications address-
ing the relationship between eNOS gene polymorphisms 
and PCa. are rare. In Safarinejad association study for 
three polymorphisms (T-786C, G894T, and 4a/b) of 
eNOS gene, detected significant differences in allelic fre-
quencies between PCa. cases and controls for the T-
786C, and 4a/b polymorphisms(10). A study in Brazil 
showed that, the GG and GT G894T genotypes present a 
3.32-fold higher risk of PCa. occurrence(40). Alterna-
tively, 161 PCa. patients were analyzed by Medeiros et 
al. but ascertained no association between eNOS G894T 
polymorphism and PCa. Regarding 4a/b polymorphism, 
they reported that the combination of the eNOS 4a/b “a” 
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with the ‘T’ allele from the G894T polymorphism in-
creases the risk of PCa. occurrence(23).  
3.3. Cell Signaling Genes: 
Cells communicate with each other by sending and re-
ceiving signals. Signals come from the environment or 
from another cell. To start a reaction, these signals must 
be transmitted across the membrane. Sometimes, the 
signal alone can pass through the membrane. In other 
cases, it acts by reacting with receptor proteins that 
communicate with both sides of the inside and outside 
of the cell. In this case, only cells that have the correct 
receptors at their levels can respond to the signal. The 
last way to escape cancerous cells is apoptosis. Cell 
membrane and organelles degradations lead to quickly 
swallowed by phagocytes(137). G proteins transmit sig-
nals between the cell surface receptor and intracellular 
signaling pathways, thereby controlling a wide range of 
biological processes such as cell growth, transcription, 
and secretion. The GNB3 825T allele is associated with 
signal transduction and alternative splicing(139). Safa-
rinejad et al. results indicated that PCa. is significantly 
associated with the T allele of the GNB3 C825T polymor-
phism and individuals homozygous for 825T had 6.24-
fold increased risk for advanced PCa. compared with 
those homozygous for the C825 allele(63). According to 
Dong et al. investigation that examined the C825T poly-
morphism in a black African population, the frequency 
of T allele in Africans was 80% vs less than 25% Euro-
peans(142), so researchers, hypothesized that this ge-
netic variant may be a factor predisposing to PCa. in the 
black population(63). 
ERBB4 is a member of the epidermal growth factor re-
ceptor subfamily of receptor tyrosine ki-
nases.  Amass  evidence displays that ErbB4 plays key 
roles in the development and prognosis of different tu-
mors(144). Hashemi et al. survived the association of 
rs12052398 T>C, rs13393577 A>G, rs13424871 A>T, 
rs16847082 A>G and rs6147150 (12-bp I/D) polymor-
phisms on risk of PCa. Although, no significant associa-
tion was detected among ERBB4 polymorphisms and 
PCa. risk(64). In China, a genome-wide association 
study (GWAS) identified the ERBB4 gene as a PCa. sus-
ceptibility gene(146). 
Fas is a cell surface receptor expressed in different types 
of tissues. Fas Ligand is one of the members of the large 
tumor necrosomal factor that interacts with Fas to send 
a cell death message to the death cell, leading to the 
death of the cell expressing Fas(147). Studies have 
shown that reducing the expression of Fas or increasing 
the expression of Fas ligand is associated with many 
types of human tumors. Polymorphism rs 2234767, 
which leads to the replacement of A instead of G and 
may reduce stimulatory protein 1 transcription factor 
binding site. These changes in the sequence of the pro-
moter region of the Fas gene can affect the expression of 
it and lead to an imbalance in cellular apoptosis and con-
tribute to carcinogenesis(66, 111). According to, Sabor 
et al. in 2018 no significant relationship was observed 
between this polymorphism and PCa. in Iranian 
men(66) and in Indian origin too(149). But, Chinese re-
searchers found an association between fas 1377 G/A 
polymorphism and PCa. on 602 patients and 703 
healthy men (140). 
The cytokine transforming growth factor-beta 1 (TGF-
b1) plays a key role in regulating the proliferation and 
apoptosis of prostate cells. Many investigations related 
to the association between TGFβ1 Leu10Pro polymor-
phism and PCa. risk, but get conflicting consequences. 
An Iranian survey showed that T allele of the TGFB1 
gene has a dominant effect on the development of PCa. 
(p = 0.009) and BPH (p = 0.005)(69). Results of a meta-
analysis with 2,604 cases and 3,129 controls appeared 
to be consistent with that (150). 
Lysosome-associated protein transmembrane-4 b 
(LAPTM4B) is an oncoprotein that is localized mostly to 
the late endosome and lysosome and is involved in can-
cer cell proliferation by upregulating the PI3K/ATK sig-
naling pathway. Based on the findings of Hashemi et al. 
LAPTM4B*2 polymorphism significantly decreased the 
risk of PCa. in Iranian population (70). A meta-analysis 
in the Chinese Han population showed that LAPTM4B 
polymorphism is associated with an increased risk of 
cancer (151). 
3.4. Cell Cycle Control Genes: 
The aberrant cell cycle is due to deregulation of the cell 
cycle and loss of cell cycle checkpoint control. Tumor 
protein 53 (TP53), is a fundamental cellular cancer sup-
pressor in multicellular organisms. The inhibitor of 
TP53 activity in the cells is Murine double minute-2 
(MDM2) oncoprotein. The results of Hashemi et al. re-
search on polymorphisms of a 40-bp insertion/deletion 
(I/D) polymorphism (rs3730485) in the MDM2 pro-
moter region and a 16-bp I/D polymorphism 
(rs17878362) in TP53 demonstrated that the MDM2 
polymorphism increased the risk of PCa. but no signifi-
cant association was seen between the TP53 16-bp I/D 
polymorphism and PCa. In agreement with them, Mittal 
et al. reported no association between the TP53 16-bp 
I/D polymorphism and PCa. in an Indian population. It 
has been suggested that the TP53 intron 3 16-bp I poly-
morphism is associated with lower levels of TP53 tran-
scripts, which offers that this duplication variant causes 
an alteration in mRNA processing and developing can-
cer. In PCa., studies of p53 codon 72 polymorphism have 
indicated different results in several populations. It has 
been suggested that the TP53 codon 72 variant may be 
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a low-penetrant risk factor for developing PCa. in Cau-
casians, but not in Asians, and polymorphisms within 
the TP53 binding sites may be valuable biomarkers for 
the prognosis of patients with PCa.(39). Babaei findings 
revealed that TP53 codon 72 polymorphism may have a 
great impact in the development of PCa. especially 
Pro/Pro with a 6.8-fold in comparison to those with 
Arg/Arg. The results study of the Behfarjam et al. were 
similar to the findings of them(58). Although, in another 
study, it is revealed that the Pro/Pro allele was corre-
lated with a strikingly less risk of PCa. (44, 152). Also, 
the findings of Doosti et al. showed that p53 Arg/Arg 
genotype could be a risk factor for the development of 
PCa. among patients in southwest Iran (51). The last 
gene in this part is atypical protein kinase C iota (aPKCι) 
oncoprotein that is encoded by the PRKCI gene. The re-
sults of Hashemi's study on two polymorphisms 
rs546950 C>T and rs4955720 C>A confirmed the asso-
ciation of rs546950 in reducing PCa. in Iranian popula-
tion (59).  
3.5. DNA Repair Pathways Genes: 
Products of the DNA repair genes help to maintain the 
genetic information of the cell and contribute to the re-
pair of the damaged DNA. In other words, it prevents 
rapid growth and proliferation with uncontrolled cells. 
Mutations in these genes disrupt the ability of cells to 
repair damaged DNA and lead to the survival of poten-
tially harmful mutations. A lot of genes has been de-
tected to be involved in the progress of the PCa. Human 
apurinic/apyrimidinic endonuclease 1 (APE1) is a mul-
tifunctional protein that has a substantial role in the 
base excision repair (BER) pathway. In 2015, 
Pournourali et al. demonstrated that the association be-
tween 1349T>G polymorphism of ApE1 gene is signifi-
cant and it could increase the risk of PCa.(22). MSH3 
gene is a member of a mismatch repair system (MMR) is 
a post-replicative DNA repair mechanism whose defects 
can lead to cancer. Jafary et al. investigated two poly-
morphisms in codon 222 and codon 1036 of MSH3 gene. 
There was significantly association between G/A geno-
type of MSH3 codon 222 and G/G genotype of MSH3 co-
don 1036 with an increased PCa. risk (P=0.012 and 
P=0.02 respectively). In a study, performed on PCa. by 
Hirata et al. indicated that the MSH3 codon 222 and 
MSH3 codon 1036 polymorphism might be a risk factor 
for PCa. in Japanese men (27). Another important DNA 
repair pathway is nucleotide exchange repair (NER). 
XPC is one of the important gene in this pathway. Hence, 
Kahnamouei et al. studied two Lys939Gln and PAT pol-
ymorphisms in 145 PCa patients and 205 Benign Pros-
tate Hyperplasia. Their results indicated the significant 
association between XPC PAT and reduction of PCa. risk 
and no association with  XPC Lys939Gln gene polymor-
phism (30). 
3.6. Regulating Gene Expression and noncoding 
RNA: 
Non-coding RNAs that play an important role in control-
ling the transcription, splicing, translation, epigenetic 
gene expression and cell cycle, recent studies have 
shown that some of them are abnormally expressed in 
PCa. They bind to the 3′untranslated regions (3′-UTRs) 
of target mRNAs and regulate gene expression. Accord-
ing to recent studies, miRNAs have a potential diagnos-
tic value in PCa.(153). Narouie et al. investigated the im-
pact of rs16917496 polymorphism at the 3′UTR of 
SETD8 on PCa. risk. This gene is involved in a different 
of biological processes, such as transcriptional regula-
tion, and genomic stability. Results have shown that the 
C allele significantly increased the risk of PCa. (p < 
0.001) compared to T allele. The findings suggested that 
the CC genotype of SETD8 is associated with low expres-
sion, which demonstrated the general mechanism of 
miR-502 mediated SETD8 expression in modifying can-
cer development (72).In another study, Hashemi et al. 
studied association between miR-499, miR-196a2, miR-
146a and miR-149 with PCa.. The findings indicated that 
CC genotype of miR-499 rs3746444 polymorphism in-
creased the risk of PCa. (P = 0.019) compared to TT gen-
otype. No statistically association was detected between 
miR-196a2 rs11614913, miR-149 rs2292832, and miR-
146a rs2910164 polymorphisms and PCa. risk. Results 
of George et al. survey presented that heterozygous gen-
otype in miR196a2 and miR-499, heterozygotes confers 
the increased risk of developing PCa. in North Indian 
population. In another investigation, Nikolic et al. have 
found no statistically significant association between 
miR-499 rs3746444 and miR-196a2 rs11614913 poly-
morphisms and PCa. risk in the Serbian population (1).  
Taheri et al. investigated the association between 
rs1333045, rs4977574, rs1333048 and rs10757278 
polymorphisms of ANRIL gene with PCa. Only the 
rs1333045 showed no significant (73). In 2017, Sat-
tarifard et al. analysis the association between 
rs13252298, rs1456315, rs7841060 and rs7007694 
polymorphisms of PRNCR1 and the risk of PCa. in Ira-
nian population. Except for rs7007694, the other poly-
morphisms are significantly associated with increased 
risk of PCa.(25). In another by Hashemi et al. 2017 a sig-
nificant association had been found between miR-34b/c 
rs4938723 polymorphism and PCa. risk(85). Moreover, 
their findings manifested that the 3-bp indel polymor-
phism could affect the expression level of miR-3131 by 
influencing the binding of splicing factor SRp20 with 
pre-miR-3131 (92). The primary method for diagnosis 
of PCa. is the prognostic antigen test (PSA), but this se-
rum marker is associated with limitations such as low 
sensitivity and specificity? In order to overcome these 
limitations, it is necessary to replace or at least improve 
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the performance of the PSA test with new biomarkers. 
Although more studies are needed to clarify the func-
tions and regulations them during tumorigenic pro-
cesses (153-155). 
3.7. Folate Metabolism Genes: 
On the pathway of folate, there are three basic genes 
that are: Methylenetetrahydrofolate Reductase 
(MTHFR), Methionine Synthase (MS), and Methionine 
Synthase Reductase (MTR). These three enzymes play a 
major role in the processes of methylation and DNA syn-
thesis. Folate maintains the balance of nucleotides 
within the cell. Disrupting the amount of folate can re-
place U instead of T in the body of DNA, which can cause 
point mutations in DNA. Two functional polymorphisms 
in the MTHFR gene have been identified C677T 
andA1298C, which have been associated with reduced 
enzyme activity. In a meta- analysis by Abedinzadeh et 
al. is stated that no find association between MTHFR 
C677T polymorphism and risk of PCa. in the subgroup 
analyses of Caucasians (103). Their results were con-
sistent with two previously published meta-analyses 
(156, 157). Also, the result of a study in Iran was no as-
sociation between this polymorphism and PCa.(93). In 
another research by Ghasemi et al. no significant associ-
ation had been found between three polymorphisms of 
FVL(G1691A), PTH (G20210A) and MTHFR 
(C677T)(110). A Case-Control Study of Methionine Syn-
thase-A2756G Transition with PCa. showed a significant 
association between G allele and PCa. Iranian men(120) 
similar to Marchal et al. investigation results (158). 
However, there is a study in China that showed no asso-
ciation between MTR A2756G polymorphism and risk of 
PCa.(159). 
3.8. Regulating Immune Responses: 
The ability of tumor cells to escape from host immune 
responses and their compatibility with different condi-
tions, and on the other hand, the use of these cells from 
peripheral biomolecules to provide materials and sig-
nals for their growth, has posed cancer as one of the 
complex and old challenges of human health (160). 
RNase L is a cytoplasmic enzyme of the innate immune 
system that destroys RNA viruses and also has a main 
role in the apoptosis of different cells. Rezaee et al. anal-
ysis of the association between RNASEL R462Q poly-
morphism and PCa. They found that AA genotype poly-
morphism was associated with increased susceptibility 
to PCa. (p= 0.02) (45). Contradictory to mentioned 
study, Babaei et al. could not find any association be-
tween RNASEL R462Q polymorphism and PCa. in Ira-
nian men (47). In a meta-analysis performed on 3009 
patients with PCa. and 703 familial prostate subjects, no 
significant association was found between RNase L 
R462Q variants and risk of PCa.(161). The results of the 
Hashemi et al. investigations showed that an association 
between 4-bp insertion/deletion (rs3783553) poly-
morphism within the 3′UTR of IL1A and PCa.(55). Alt-
hough, Liao et al.’ study stated that allele I is associated 
with the reduced PCA. risk (P=0. 001)(60). 
3.9. Renin–Angiotensin System: 
The renin–angiotensin system (RAS) involved in regu-
lating blood pressure and cardiovascular homeostasis. 
An enhanced RAS activity has been proposed to play a 
role in neoplastic cell proliferation and metastasis. An-
giotensin I-converting enzyme (ACE) is the key enzyme 
of RAS and to be expressed differentially in several car-
cinomas and may be signify in migration of tumor cells 
and tumor angiogenesis. The Alu repetitive sequence in-
sertion/deletion (I/D, rs4646994) polymorphism in the 
ACE gene has been implicated in cancer susceptibility 
(162). A case-control study on 95 patients with PCa. and 
111 patients with benign prostatic hyperplasia by Ha-
sanzad et al. showed no association between the ACE 
gene insertion/deletion (I/D) polymorphism and can-
cer risk(129). The results of a meta-analysis found that 
a significant association between ACE I/D polymor-
phism and PCa. (163). 
3.10. Hormone Synthesis and Metabolism: 
Reviews have shown that changes in steroid hormone 
metabolism, specifically involving testosterone, influ-
ence the risk of PCa. CYP17 and CYP19 genes are in-
volved in metabolism pathways of testosterone and es-
trogen, respectively (67, 83). Similar to Iranian study 
more studies have shown a significant association be-
tween an A2 allele of CYP17 gene and risk of PCa. (67, 
164).  A study had conducted by Souiden et al. mani-
fested that genotypes containing the A2 allele is associ-
ated with increased risk of PCa. (P value=0.029) (165). 
Some investigations have illustrated a significant differ-
ence between case and control groups in genotype 
groups of TTTA variant in CYP19 gene (83). For exam-
ple, Latil et al. showed 171 and 187 alleles are associ-
ated with PCa. risk (P-value=0.05 and 0.045, respec-
tively) (166). A study was conducted by Farzaneh et al. 
found no association between various length of tetranu-
cleotide repeats and PCa., risk (with P-value=0.4)(83).  
Microseminoprotein-beta (MSMB) is one of the most 
plentiful proteins in human seminal plasma. GWASs rec-
ognized rs10993994 polymorphism in the promoter re-
gion of MSMB gene, which was significantly associated 
with PCa. susceptibility. In a meta-analysis disclosed 
that this SNP was associated with an increased risk of 
PCa. among Caucasians, while no association was dis-
covered among Asians. As for other populations, a weak 
association among African-Americans and mixed popu-
lations had been found (167). Also, the result of Shahkar 
et al. investigation showed that MSMB rs10993994 pol-
ymorphism increased the risk of PCa. in an Iranian pop-
ulation(97). 
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Sex hormones have been signified in prostate carcino-
genesis and are thought to adjust cell proliferation and 
growth (119). In 2016 Tahmasebi Fard et al. studied the 
association between the Asp327Asn Polymorphism of 
SHBG gene and PCa. They demonstrated that homozy-
gous mutant genotype AA (p value= 0.007) and hetero-
zygous AG (p-value =0.51) increase risk of getting PCa. 
in carriers(168). In Berndt’s review, stated that SHBG 
D356N polymorphism, heterozygotes were found to 
have an increased risk of PCa. among whites (P = 
0.0007) (119). 
Estrogen impacts are mediated by two estrogen recep-
tors ER-α and ER-β. The association between ER-α and 
ER-β genes variants and PCa. have been addressed in 
very few reviews. Safarinejad et al. found that the ER-a 
Pvull C, ER-a XbaI G,and ER-b AluI G alleles were signif-
icantly associated with an increased risk of PCa.(113). A 
study of 170 PCa. patients in Indian population found a 
significant difference in Pvull polymorphism of ER-a 
gene distribution between patients and controls(169). 
In a large population-based case-control investigation 
(1,415 cases and 801 controls) 28 SNPs spanning the 
entire ER-β gene were checked out. Only for one of the 
typed htSNPs (rs2987983) found a significant differ-
ence in allele frequency between cases and controls 
(170). 
3.11. Androgen Receptor (AR): 
The prostate is an androgen-dependent organ and 
genes that are involved in the signaling pathways and 
metabolism of these hormones have been implicated as 
factors involved in the initiation or progression of pros-
tate adenocarcinoma. The N-terminal domain of the AR 
gene has polymorphic trinucleotide repeats CAG, encod-
ing polyglutamine. Studies have illustrated that the 
number of CAG repeats is associated with a risk of PCa. 
In the same way, Ashtiani et al. studied the CAG repeat 
length of AR gene in Iranian patients and stated that CAG 
repeat polymorphism in AR gene may act as a risk mod-
ifier (12). Also, in 2016 researcher found that patients 
with ≤21 CAG repeats have an increased risk of develop-
ing PCa. (P<0.001) and the combination of ≤21CAG and 
≥17 GGC repeats was associated with the risk of devel-
oping PCa.(171). 
Glucuronidation is the main pathway for removal of ex-
ogenous and endogenous compounds such as environ-
mental carcinogens and androgens from the body. This 
biochemical pathway is mediated by enzymes called ur-
idine diphospho glucuronosyl transferases (UGTs). 
Three UGT2B classes of enzymes (UGT2B15, UGT2B17, 
and UGT2B28) inhibit the agglomeration of androgens 
in the prostate. In 2017 Iranian investigators reported 
D85Y polymorphism of UGT2B15 and CNVs in UGT2B28 
and UGT2B17 genes is not associated with PCa. risk. 
There are many conflicting data about the association 
between the two UGT2B17, UGT2B28 polymorphisms 
and the risk of the disease (35). Karypidis et al. reported 
an association betweenUGT2B17 variation and the risk 
of PCa. in Caucasian population (172). To date, investi-
gations have displayed UGT2B17 gene deletion is more 
prevalent among populations than whole gene deletion 
of UGT2B28. The association between del/del genotype 
of UGT2B28 and the risk of cancers was shown in vari-
ous survives (35). Null genotype of UG-T2B28 has been 
linked to a higher risk of biochemical PCa. relapse (173). 
Gsur et al. presented no significant association between 
D85Y polymorphism of UG-T2B15 and the risk of PCa. 
(174). 
Prostate-specific antigen (PSA) is a serine protease that 
is part of the kallikrein superfamily, usually produced 
by prostate cells. It has widely been used as a diagnostic 
marker of the PCa. since the early 1990s. The main reg-
ulators of PSA expression at the gene level are andro-
gens. Production of PSA is mediated through binding of 
the androgen receptor (AR) to androgen response ele-
ments (ARE) in the promoter region of the PSA gene 
(38). There are two different reports on the association 
of this SNP with serum PSA level in the Japanese popu-
lation. One showed an association between higher PSA 
level and GG genotypes and the other showed no associ-
ation between PSA-158 G/A polymorphism and the se-
rum PSA level (175, 176). In a study conducted on 
95cases and 111contol in Iran, no significant association 
was found between rs266882 and PSA plasma levels 
(38). A case-control study on patients with Turkish 
origin reported that ARE-1 PSA polymorphism has a sig-
nificant influence on PCa. risk (177).  
3.12. Drug Metabolizer, Detoxification and Re-
sistance: 
Glutathione S-transferase (GST) is super family genes 
that encode enzymes which plays a key role to protect 
from DNA damage and detoxification of the cell. GSTM1, 
GSTP1, and GSTT1 are most widely studied in molecular 
epidemiology of cancer. Large genomic deletions of 
GSTM1 and GSTT1 (null genotype) result in a complete 
lack of enzyme activities. GSTP1 polymorphism 
(Ile105Val) produces an enzyme with decreased activ-
ity. A large number of studies related to the association 
between GST variations and PCa. risk, but get conflicting 
results. For example in Iran, Ansari et al. found no asso-
ciation between GSTT1 and GSTM1 gene polymor-
phisms and PCa.(3) but  Safarinejad study detected a 
significant association between the null genotypes of 
GSTM1, GSTT1 and the Val allele of GSTP1 with a higher 
risk for PCa.(18). They stated that the frequency of the 
GSTM1 null genotype is ~50% of the Caucasian popula-
tion in Europe. In this study, the frequency of the GSTM1 
null genotype in the Iranian population was 43%, a rate 
compatible with that reported by Lai et al (18, 178). In 
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another survey, the association between GSTM1 null 
genotypes and PCa. risk was confirmed (12). Similar to 
the Indian (179) and German population, a positive as-
sociation have been found between the increased risk of 
PCa. with the GSTT1 null genotype but not in the Amer-
ican population (18). Study of the articles about the im-
pact of the GSTP1 gene on PCa., disclosed a significant 
association between heterozygous GSTP1 genotype 
(Ile/Val) and PCa.(18). However, two further case-con-
trol studies reported no association between GSTP1 and 
PCa. risk (18, 180). 
ABCC1 (MRP1) is a member of the ATP-binding cassette 
superfamily of cell-surface transport proteins and is in-
volved in drug resistance and cellular antioxidative de-
fense system. SNPs in the coding region of the ABCC1 
gene have been revealed to affect its function(181). Re-
sults showed that the AA genotype in ABCC1 in patients 
is higher than controls and are correlated with the risk 
of PCa. in Iranian population(58). On the other hand, a 
report by Zhao et al., indicated that promoter polymor-
phism of the ABCC1 gene too, is associated with cancer 
development(58). Evidence indicated that SNPs within 
the ABCC1 (MRP1) are important in predicting the re-
sponse to chemotherapy in different cancers(182). 
SNPs in the promoter region of a gene can potentially 
alter the affinity of interactions between DNA and nu-
clear proteins and, so that, affect the efficiency of tran-
scription(58). 
NAT2 enzyme participates in bioconversion of hetero-
cyclic arylamines and aromatic amines to electrophilic 
ions that can be critical initiators of the tumorigenesis 
process(183). NAT2 is most frequently expressed in the 
liver and implicates a variant which results in the ex-
pression of four mutant alleles. In 2017, Hasanzad et al. 
study demonstrated that carrying G857A, G590A and 
T481C polymorphisms of NAT2 may not affect develop-
ing PCa., but heterozygote genotype of T481C polymor-
phism can be associated with more advanced stages of 
cancer earlier in life(54). Steivastava et al. in a study of 
130 patients and 140 controls of an Indian population 
found no significant association between NAT2 geno-
type and PCa. risk(184) that was in agreement with the 
findings of Wadelius et al. in Swedish and Danish popu-
lations(43).  
It has been shown that activated estrogens are associ-
ated with several tumors in various tissues and the 
within catechol-o-methyltransferase (COMT) enzyme is 
responsible for this defense. It has been shown in some 
studies that single nucleotide polymorphisms COMT 
genes have been associated with benign prostatic hy-
perplasia and PCa.. The COMT gene has three polymor-
phic sites at codons 62, 72 and 158. The results of Om-
rani et al. did not show any association between the 
Met158 polymorphism and PCa.(80) but in Japan, re-
searchers stated that G/A genotype of the COMT gene is 
associated with a weak tendency toward increased 
prostate carcinoma risk(185).  
To unravel any possible specific genetic aberration in 
Iranian population in compare with the rest of the 
world, we compared the results of the association be-
tween polymorphisms and the risk of prostate cancer 
between Iran and other countries. The result high-
lighted 11 genes which were different (Table 2, red 
numbers). For example, rs1256049 polymorphism in 
ER-β gene was significant in Iranian patients, while in 
other countries with a high sample size, such as America 
and China, no significant difference was found. 
 
4. Discussion 
Cancer is the third cause of death in Iran (186) and 
based on Globocan 2012, among Iranian men, PCa. is 
one of the most common cancers (187). One of the rea-
sons for the inconsistency between the Globocan's and 
Iran's reported incidence rate could be due to different 
estimates and sources of information in Iran (188). The 
lowest ASR was belonged to Kerman province (3.2 per 
100,000), in Iran(189). Globally, it is estimated that the 
highest Standardized Incidence Ratio (SIR) is related to 
countries in the Oceania region, such as Australia (111.6 
per 100,000), and North America (97.2 per 100,000). 
The result of Hassanipour’s review showed that the in-
cidence of PCa. in Iran is low (ASR = 9.11 per 100,000), 
whereas the Asian countries such as Turkey (40.6 per 
100,000) and Lebanon (37.2 per 100,000) have a high 
SIR. However, the lowest incidence rate was reported 
for South-Central Asian countries (4.5 per 100,000), and 
South East Asia (5.5 per 10 0,000)(190-192) In spite of 
numerous investigation attempts throughout the world, 
and the publication of various articles each year, the 
presumed association between specific genetic varia-
tions and cancer risk remains unknown. This contro-
versy is raised from a small sample size and has been 
intensified currently by the development of high-
throughput technology to precisely recognize SNPs 
(193). The etiology of PCa. is improbable to be clarified 
by allelic variability. Instead, the prevalence of PCa. in 
the population likely follow by complex interactions 
among many genetic and environmental factors over 
time. The most of PCa. cases are improbable to be due to 
significant susceptibility genes and genetic polymor-
phisms are presumably to be more valuable from a pub-
lic health perspective. Its incidence rates are constantly 
rising because of increases in longevity and it is ex-
pected that in the future, the numbers of cancer cases 
will be growth in Iran (194). The results of associations 
of polymorphism with the incidence and severity of 
prostate cancer between Iran and other countries re-
quire more research. It is quite clear-cut that in order to 
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Table 2: Specific genetic aberration in Iranian population in compare with the rest of the world 
IRAN Other Countries 











102/139 P= 0.1 (4) Asian India 190-200 p = 0.026 (7) 
50/54 P = 0.72 (5) Latin Brazil 100-100 P <0.00 (13) 
         
eNOS- G894T 352/356 P = 0.001 (10) Caucasians Serbia 150-100 P > 0.05 (19) 
95/111 P =0.2 (14) Caucasians Portugal 125-153 p=0.037 (23) 
   Eurasians Turkey 193-85 p>0.05 (24) 
   Eurasians Turkey 84/116 P=.0001 (29) 
eNOS-4a/b 352/356 P = 0.004 (10) Eurasians Turkey 84/116 P =.003 (29) 
eNOS- T-786C 352/356 P = 0.001 (10) Latin Brazil 83-94 P=1.0 (40) 
   Eurasians Turkey 84/116 P = .026 (29) 
         
VEGF-C460 T 50/50 P=0.031 (17) Eurasians Turkey 133-157 P > 0.05 (57) 
    Asian Taiwan 96-119 P<0.001 (61) 
         
ApE1-
1349T>G 
100/100 P= 0.045 (22) Caucasians USA 228-335 P=0.03 (71) 
   Asians China 198-156 p = 0.02 (76) 
         
MSH3 
Pro222Pro 
18/60 P=0.012 (27) Asians Japan 110-110 P>0.05 (82) 
         
XPC T>G 154/205 P>0.05 (30) Asians China 1,004- 1,055 P>0.05 (86) 
   Caucasians USA 1457- 1351 0.97 (88) 
   Caucasians Poland 720 -1121 0.68 (89) 





(12) European Europe 1744 cases P < 
0.0005 
(99) 
   Caucasians 
and Black 
USA 1159 -1353 P>0.05 (104) 
   Sweden Sweden 1,461-796 P = 0.03 (106) 
         
UGTB15,17,28 120/120 P>0.05 (35) - USA 233-342 p < 0.05 
UGTB15 
(108) 












         
PSA 95/111 P =0.7 (38) ----------- Australia 821-734 P =.001 (121) 
   ------------ Portugal 151-127 P = .009 (123) 
         
MDM2 103/142 P=0.023 (39) Mixed Norway 5002-7498 P>0.05 (124) 










40/80 P = 
0.005 
(44) Caucasians Slovakia 300-446 P<0.05 (133) 
68-85 P = 0.98 (49) Caucasians Germany 510-490 P>0.05 (134) 
187/185 P>0.001 (51)      
45/45 p<0.05 (58)      








(59) Asian China 1015-1044 P = .045 (136) 
         
GNB3 C825T 172/344 p = 
0.003 
(63) Caucasians Germany 235-111 p= 0.82 (138) 
         
FAS- G1377A 100/100 P>0.05 (66) Asian China 602-703 P= 0.03 (140) 
    northern 
India 
India 192-224 P = 0.02 (143) 
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Table 2 continue: Specific genetic aberration in Iranian population in compare with the rest of the world 
IRAN Other Countries 
miR-499 169/182 P = 
0.019 
(1) Caucasian Serbia 355-312 P<0.05 (2) 
   Asian India 159-230 P ≤ 
0.001 
(8) 
         
miR-146a 169/182 P>0.05 (1) Caucasian Serbia 286-199 p =.006 (9) 
   Asian China 251-280 P = 0.01 (15) 
         
miR-196a2 169/182 P>0.05 (1) Caucasian Serbia 355-312 P>0.05 (2) 
   Asian India 159-230 P = 0.01 (8) 
         
PRNCR1 
rs13252298 
178/180 P=0.231 (25) Asian China 286-288 P>0.05 (26) 
   Caucasian USA 943-2829 0.093 (28) 





(25) Caucasian USA 40-40 P=.002 (37) 
    Asian China 495-640 P=2.81×
10-4 
 





(25) Mix USA 10501- 
10831 
P<0.05 (42) 
         
RNASEL 181-19 P<0.05 (45) European Sweden 1,622-796 P=0.627 (46) 
40/80 P=0.3 (47) European USA 1,116-1,344 P=0.237 (52) 
   Mix Canada 996-1,092 0.463 (53) 
         
IL1A 
rs3783553 
150/155 P<0.05 (55) Asian China 131-229 P=. 001 (60) 
         
CYP17 
rs743572 
74/128 P<0.05 (67) Caucasian USA 804-1357 P = .014 (74) 
150-150 P=0.041 (77) Mix USA 8,138-9,033 P>0.05 (79) 
         
CYP19 59/95 P =0.4 (83) Caucasian France 1,101-882 P =.003 (87) 
   Asian Taiwan 244-261 P=  0.15 (91) 
   ------- Bulgaria 246-261 P<0.05 (95) 
         
MSMB 
rs10993994 
169/182 P = 0.03 (97) Caucasian USA 10 487- 11 
024 
p<0.05 (98) 
   African-
American 
USA 4,040- 3,748 P=.005 (100) 
   Caucasian Sweden 2899- 1722 P =.001 (101) 
MSMB 
rs12770171 
169/182 P>0.05 (97) Asian -In-
dian 
India 33-60 P>0.05 (107) 
         
SHBG 
rs6259 
120/120 P<0.05 (111) Caucasian USA 937-493 P>0.05 (115) 
   Caucasian USA 1,320-1842 p<0.05 (119) 
         
ER-a 
rs2234693 
162/324 P = 
0.002 




   Caucasian USA 1,320-1842 P>0.05 (119) 
   Asian Japan 750-870 P>0.05 (135) 
ER-a 
rs9340799 
162/324 P = 
0.002 
(113) Mixed USA 598-1,098 p<0.05 (126) 
   Mixed USA 609-843 P>0.05 (74) 











162/324 P = 
0.003 
(113) Asian Japan 750-870 P < 0.05 (135) 
   Caucasian France 1045-814 P>0.05 (145) 
ER-β 
rs1256049 
162/324 P = 
0.003 
(113) Caucasian France 1045-814 P>0.05 (145) 









   Caucasian USA 5,946-6,576 P>0.05 (148) 
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achieve certainty, the need for further studies with high 
numbers of samples in Iranian men with prostate can-
cer is required, as well as the writing of meta-analytic 
articles related to the target polymorphism. Harmoniz-
ing the methods of studies may minimize the confound-
ing factors to achieve a better study outcome. The pur-
pose of these kinds of researches and writing of system-
atic and meta-analytic articles is that, in the future, using 
the results of them, it would be possible to predict the 
incidence of prostate cancer in susceptible individuals. 
For many of the genetic polymorphisms reviewed in this 
article, association with PCa. have been contradictory 
across investigations, which perhaps due to methodo-
logic or sample size limitations or dissimilar in the basic 
frequencies of alleles. Many studies recognized in this 
review used available samples of cases and controls and 
were not really population-based. In some researches, 
there may have been insufficient control of confounding 
Table 2 continue: Specific genetic aberration in Iranian population in compare with the rest of the world 
IRAN Other Countries 














   Caucasian USA 590-538 p<0.05 (11) 
110/100 P <.0001 (12)      
168/336 P=0.005 (18)      














110/100 P>0.05 (12) Caucasian USA 590-538 P>0.05 (11) 
168/336 P=0.005 (18)      
GSTP1 168/336 P=0.002 (18) Mixed USA 2,528- 3,076 
Meta-analy-
sis 
P < 0.01 (41) 
   Caucasian Sweden 850 P>0.05 (43) 
   Caucasian Austria 166-166 p<0.05 (48) 
         





   African 
Americans 
USA 254-301 P>0.05 (68) 
   Asian 
Caucasian 






         
COMT 
rs4680 
41/193 P=0.021 (80) African France 660-709 p<0.05 (81) 
   Caucasian British 89-178 P = 0.15 (84) 




         
MTHFR 
rs1801133 
67/75 P=0.20 (93) Caucasian Norway 3000-3000 P>0.05 
 
(96) 
174/ 348 P=1.0 (102) Caucasian Sweden 2777- 1639 P=0.46 
 
(105) 
30/40 P>0.05 (110)      
MTHFR 
rs1801131 
174/ 348 P=0.08 (102) Caucasian USA 439 - 479 P = 0.08 
 
(117) 
   Caucasian USA 1,144 - 1,144 p<0.05 
 
(118) 
         
MTR 
rs1805087 
100/100 P=0.99 (120) Asian China 1871-2026 P=0.9 (127) 
   Caucasian Russia 370-285 P=0.5 (128) 
         
ACE 95/111 P>0.05 (129) Caucasian Nether-
lands 
209-6,015 P>0.05 (131) 
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factors. The prevalence of environmental risk factors, 
and the unknown etiologic factors may also differ across 
populations. This manuscript discussed molecular stud-
ies of polymorphisms and PCa. risk that have cases and 
controls from different racial and ethnic groups in Iran. 
The results from mention study can be used as evidence 
for gene-gene interactions. Although, social-environ-
mental factors and gene-environment interactions, may 
also give a reason for discrepancies in PCa. incidence 
and mortality. Some authors have mentioned that, ge-
netic polymorphism within racial and ethnic groups is 
higher than the genetic variation that exists across ra-
cial, ethnic, or cultural groups. There has been still on-
going controversy over the association between the 
gene polymorphisms and PCa. susceptibility. Further 
studies that assay associations among various genetic 
polymorphisms should take into account risk factors for 
PCa., such as diet and environmental exposures, possi-
ble biological pathways and gene-gene-environment in-
teractions(36). Despite the existing clinical parameters, 
new biomarkers are needed to improve the prognosis. 
Some molecules and DNA-based genetic biomarkers are 
under survey as potential prognostic factors (195).  
 
5. Conclusion: 
In conclusion, performing more investigations are 
needed to map out the precise incidence rate and trend 
of PCa. in Iran. Albeit several studies had been done in 
this area, most of them were local or performed in the 
past years and must be updated. It would be essential to 
fulfill well-powered researches on SNPs to obtain defi-
nite results regarding their predictive role and in regard 
to their function in the PCa. development pathway, 
which could be considered as therapeutic targets.  
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